Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial
Journal
Lancet (London, England)
Journal Volume
399
Journal Issue
10336
Pages
1708
Date Issued
2022-04-30
Author(s)
Nguyen, Trong Toan
Chiu, Cheng-Hsun
Lin, Chien-Yu
Chiu, Nan-Chang
Chen, Po-Yen
Le, Thi Tuong Vy
Le, Dang Ngan
Duong, An Han
Nguyen, Van Luan
Huynh, Thi Nguyet
Truong, Huu Khanh
Phan, Trong Lan
Nguyen, Thi Thanh Thao
Shih, Shin-Ru
Huang, Chung-Guei
Weng, Yi-Jen
Hsieh, Erh-Fang
Chang, Stanley
Chen, Charles
Tai, I-Chen
Abstract
Children are susceptible to severe or fatal enterovirus 71 (EV71) infections. We aimed to evaluate the efficacy, safety, and immunogenicity of EV71vac, an aluminium phosphate-adjuvanted inactivated EV71 vaccine in children aged 2-71 months.
Subjects
MOUTH-DISEASE; FOOT; HAND; PATHOGENESIS; CHINA
Publisher
ELSEVIER SCIENCE INC
Type
journal article